The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. Guidelines for Treating HIV Get Updated

February 2011

The U.S. Department of Health & Human Services announced an update to the federal Guidelines for treating HIV on January 10, 2011. The revisions are mostly small changes to using certain HIV meds, CD4 counts and viral load test results. Other changes include treating people co-infected with hepatitis B or tuberculosis.

What to Start: Changes for People Going on Treatment for the First Time

The Guidelines describe several groups of regimens when starting HIV treatment: "preferred," "alternative," "acceptable/may be acceptable" and "may be acceptable but used with caution." The first group includes regimens that generally are more tolerable and the most potent. Each group after begin to have increasingly more disadvantages than the one before it. The new recommendations highlight three changes in first line treatment:

  • A regimen with Selzentry + Combivir has been upgraded to "acceptable" because of stronger data from a randomized study.
  • "Selzentry + Truvada" and "Selzentry + Epzicom" have been added as "may be acceptable."
  • In response to a recent product label change to saquinavir (Invirase),
  • Regimens with Invirase + ritonavir have been downgraded from "alternative" to "may be acceptable but used with caution" due to increased risk for heart rhythm problems.

CD4 Counts

A small change was made in recommending how often CD4 counts are done. The new recommendation is that the CD4 count may be monitored less often, for example every 6-12 months (instead of every 3-6 months). This applies to those who are on treatment and remain undetectable with no new changes in their general health, such as new HIV symptoms or having to start medicines that affect the immune system (interferon, corticosteroids, etc.)

Viral Load Tests

Low-level results (typically <200) are commonly reported from some viral load tests. These results tend to be caused more by isolated "blips" due to the test's variability rather than being an actual increase in viral load. The new recommendation cautions providers not to use "detectable" viral load below 200 as a reason to switch treatment. Trends over time, such as a continually increasing viral load with two or more tests, are more accurate predictors of treatment success or failure.

Drug-Resistance Testing for Integrase Inhibitors (INSTIs)

HIV resistance is a concern for any HIV drug, including the newest class of integrase inhibitors. However, standard genotypic tests only check for mutations for the NRTIs and protease inhibitors. The new recommendations encourage providers to order genotypic tests specifically for integrase inhibitors in addition to other genotypic tests done.

Tuberculosis Disease With HIV Co-Infection

All HIV-positive people with active TB should be treated with HIV treatment. For patients with <200 CD4s, HIV treatment should be started within 2-4 weeks of starting TB treatment. For patients with 200-500 CD4s, the Guidelines Panel recommends starting HIV treatment within 2-4 weeks, or at least within 8 weeks, after starting TB treatment. For patients with >500 CD4s, most Panel members also recommend starting HIV treatment within 8 weeks of TB treatment.

Hepatitis B Disease With HIV Co-Infection

This section has been revised to provide recommendations for managing co-infected people, including those with HBV infection resistant to 3TC or FTC and for patients who cannot tolerate tenofovir (Viread).

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. Visit Project Inform's website to find out more about their activities, publications and services.
See Also
Read the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF)
More News and Analysis on HIV Treatment Guidelines

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: